ADC Therapeutics Future Growth
Future criteria checks 2/6
ADC Therapeutics is forecast to grow earnings and revenue by 27.4% and 33.5% per annum respectively while EPS is expected to grow by 37.2% per annum.
Key information
27.4%
Earnings growth rate
37.2%
EPS growth rate
Biotechs earnings growth | 27.9% |
Revenue growth rate | 33.5% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 16 Oct 2024 |
Recent future growth updates
Recent updates
ADC Therapeutics SA (NYSE:ADCT) Surges 34% Yet Its Low P/S Is No Reason For Excitement
Jul 18Limiting Concerns On ADC Therapeutics' Prospects
Jun 06ADC Therapeutics SA's (NYSE:ADCT) 26% Dip In Price Shows Sentiment Is Matching Revenues
May 30Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter Results
May 10ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)
Mar 19ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues
Mar 17ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth
Jan 18ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial
Dec 29An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued
Dec 14ADC Therapeutics: Navigating A Swirling Drain
Dec 01ADC Therapeutics: Slowly Moving Toward Solvency
Aug 29Are Investors Undervaluing ADC Therapeutics SA (NYSE:ADCT) By 32%?
Jul 11ADC Therapeutics: Maybe A 2024 Story
May 29Analysts Have Just Cut Their ADC Therapeutics SA (NYSE:ADCT) Revenue Estimates By 28%
May 11ADC Therapeutics SA's (NYSE:ADCT) Shares Lagging The Industry But So Is The Business
Apr 18ADC Therapeutics stock slips after pricing stock offering by seller
Feb 02Does ADC Therapeutics (NYSE:ADCT) Have A Healthy Balance Sheet?
Jan 16Jose Carmona joins ADC Therapeutics as CFO
Dec 19ADC Therapeutics Non-GAAP EPS of $0.13, revenue of $76.32M
Nov 08ADC, Sobi Zynlonta for blood cancer subtype gets EMA panel backing for EU approval
Sep 16ADC Therapeutics gets downgraded at Morgan Stanley, price target cut to $11
Sep 09ADC Therapeutics Non-GAAP EPS of -$0.73, revenue of $17.29M misses by $13.93M
Aug 09Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 113 | -147 | -107 | -245 | 6 |
12/31/2025 | 84 | -160 | -100 | -169 | 7 |
12/31/2024 | 73 | -160 | -68 | -147 | 7 |
6/30/2024 | 67 | -215 | -147 | -145 | N/A |
3/31/2024 | 69 | -227 | -150 | -147 | N/A |
12/31/2023 | 70 | -240 | -122 | -119 | N/A |
9/30/2023 | 123 | -182 | -139 | -138 | N/A |
6/30/2023 | 184 | -184 | -103 | -102 | N/A |
3/31/2023 | 182 | -200 | -120 | -120 | N/A |
12/31/2022 | 210 | -157 | -139 | -138 | N/A |
9/30/2022 | 157 | -166 | -149 | -146 | N/A |
6/30/2022 | 94 | -187 | -212 | -207 | N/A |
3/31/2022 | 80 | -195 | -219 | -212 | N/A |
12/31/2021 | 34 | -230 | -240 | -233 | N/A |
9/30/2021 | 17 | -252 | -230 | -223 | N/A |
6/30/2021 | 4 | -200 | -215 | -209 | N/A |
3/31/2021 | N/A | -254 | -195 | -192 | N/A |
12/31/2020 | N/A | -246 | -172 | -169 | N/A |
9/30/2020 | N/A | -226 | -153 | -151 | N/A |
6/30/2020 | N/A | -237 | -140 | -139 | N/A |
3/31/2020 | 1 | -135 | -128 | -126 | N/A |
12/31/2019 | 2 | -116 | -124 | -122 | N/A |
9/30/2019 | 3 | -112 | -121 | -118 | N/A |
6/30/2019 | 3 | -111 | -119 | -116 | N/A |
3/31/2019 | 2 | -117 | -122 | -118 | N/A |
12/31/2018 | 1 | -123 | -124 | -121 | N/A |
12/31/2017 | 2 | -90 | N/A | -75 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ADCT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ADCT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ADCT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ADCT's revenue (33.5% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: ADCT's revenue (33.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ADCT's Return on Equity is forecast to be high in 3 years time